Pharmacovigilance Specialist Job Description

A Pharmacovigilance Specialist runs the daily safety surveillance that a drug or biologic sponsor owes regulators from the first dose in a clinical trial onward. The work happens in a drug safety department, either at the company that holds the application or at a service provider that processes cases for sponsors under contract. In both settings the output is the same: adverse event information turned into coded, assessed and submitted case records that will hold up in an inspection.

The basic unit is the individual case safety report. A report can arrive from a nurse calling a medical information line, a patient filling in a web form, a field representative, a journal case report, a licensing partner or a trial investigator. The specialist checks that the report describes a real patient, a reporter, a suspect product and an event, opens a case in the safety database, codes the terms in MedDRA, and writes a narrative that tells a physician reviewer what happened and when.

Two classifications set the deadline. Seriousness asks what the event did to the patient; expectedness asks whether the product's labeling or reference safety information already lists it. Under FDA's postmarketing rule, 21 CFR 314.80, a sponsor must report each adverse drug experience that is both serious and unexpected "as soon as possible but no later than 15 calendar days" from first receipt. Other postmarketing cases go into periodic reports, which the same rule requires at quarterly intervals for 3 years from approval and then at annual intervals. In development, the IND safety rule, 21 CFR 312.32, gives a sponsor no more than 7 calendar days to notify FDA of an unexpected fatal or life-threatening suspected adverse reaction. Because the postmarketing clock runs from initial receipt of the information by the applicant, intake speed matters as much as medical accuracy.

Follow-up takes real time. A first report may be thin, so the specialist drafts queries for onset dates, lab results, concomitant drugs and outcomes, sends them on a set schedule, and updates the case as answers return. Every follow-up can change the seriousness call or the coding, and some trigger a new submission.

Above single cases sits aggregate work. Specialists pull case series for a safety topic, prepare the line listings and tables behind a periodic benefit-risk evaluation report or development safety update report, and bring data to signal review meetings where safety physicians decide whether a pattern deserves formal evaluation. A confirmed signal can lead to a labeling change, a letter to prescribers or a change to a risk evaluation and mitigation strategy.

The quieter half of the job is quality. Specialists reconcile the safety database against clinical and partner data, keep SOPs and training records current, close corrective actions from audits, and pull evidence for regulators on short notice.

As a rough guide, the path into pharmacovigilance starts with clinical or scientific training, because the job asks you to read a medical record and judge what it says about a drug. The usual starting point is a bachelor's degree in pharmacy, nursing, biology, biochemistry, pharmacology or public health. A PharmD, an RN license, or experience as a physician assistant, paramedic or clinical research coordinator are all workable backgrounds, and each brings something to the desk: a pharmacist brings dosing and interaction knowledge, a nurse brings practice reading hospital charts and timelines, and a research coordinator already knows how trial sites record serious adverse events.

As a rough guide, people reach the specialist title after 1 to 3 years in an entry role, often called drug safety associate or case processor, where they learn intake, coding and narrative writing under review. Again as a rough guide, senior specialist and safety scientist roles follow after another 2 to 4 years, once the person has handled aggregate reports and signal work as well as single cases.

Regulatory knowledge to build early

• FDA safety reporting rules for INDs and marketed drugs, including the definitions of serious, unexpected and suspected adverse reaction
• The format and business rules FDA applies to electronic case submissions, and how a rejected file is corrected and resent
• Company SOPs, safety data exchange agreements with partners, and the reference safety information for each product you handle
• Inspection basics: what an investigator asks for, and how an audit trail shows who changed a case and why

Technical skills

• MedDRA coding at the lowest level term and preferred term levels, and building standardized queries for case retrieval
• WHODrug coding for suspect and concomitant products
• Working knowledge of at least one safety database, such as Oracle Argus Safety, Veeva Vault Safety or ArisGlobal LifeSphere Safety
• E2B(R3) data elements and the validation errors that cause a regulator to reject a file
• Literature searching in Embase and PubMed, plus enough Excel or SQL to build a line listing without help

Credentials

• Pharmacist license from a state board of pharmacy, or a registered nurse license from a state board of nursing, for candidates coming from clinical practice
• Regulatory Affairs Certification, RAC-Drugs, from the Regulatory Affairs Professionals Society (RAPS), for specialists who expect to move toward regulatory strategy or labeling work

The job itself carries no license of its own. Without one, the useful evidence to offer is narrative quality, coding accuracy and a clear grasp of why a reporting clock started when it did. A short writing sample built from a fictional case is a useful thing to bring to an interview.

BLS does not publish a separate count or wage for pharmacovigilance specialists. The closest occupation in its data is compliance officers, the group that O*NET's regulatory affairs specialist title belongs to. In the May 2025 OEWS industry data, pharmaceutical and medicine manufacturing employed 5,380 compliance officers. Scientific research and development services employed 11,470 compliance officers, at a median of $107,410. Nationally, across every industry, the occupation's median was $80,730. None of these rows isolates drug safety staff, so read them as the nearest public benchmark rather than a pay figure for the title.

For outlook, O*NET rates projected growth for compliance officers as Average (3% to 4%) for 2025 to 2035, with about 32,700 openings a year on average across the whole occupation. That projection covers compliance officers in every industry, not only drug safety teams, so it says little about pharma hiring in any given year.

In 2026, FDA also changed how it receives cases. As of April 1, 2026, FDA requires premarketing IND case safety reports in electronic format using E2B(R3) data standards. FDA accepted E2B(R2) files from companies that had not yet switched only through September 30, 2026, and since October 1, 2026, all case reports submitted through the ESG NextGen gateway must go to the AEMS database in E2B(R3). For a safety team, a format switch like that means remapping database fields, testing transmissions, and working through rejected files case by case. Knowing the data elements behind a submission, not only the screens, helps when tracing a rejection.

Automation is the other change worth watching. FDA's Center for Drug Evaluation and Research runs the Emerging Drug Safety Technology Meeting program, which gives approved applicants and other parties, including contract research organizations and pharmacovigilance vendors, a chance to meet CDER staff to discuss their research, development and use of AI and other emerging technology. In a July 2025 Federal Register notice, FDA said it anticipates an increase in the number of meetings granted, to expand its understanding of how AI-enabled tools and other emerging technologies are being used for pharmacovigilance.

The career ladder runs from specialist to senior specialist, then to safety scientist, signal management lead or pharmacovigilance manager, and on to head of drug safety. Each step adds scope: a senior specialist reviews other people's cases and owns the timeline for a product's periodic reports, a safety scientist designs case retrieval strategies and drafts signal assessments, and a manager handles vendor oversight, staffing and inspection readiness for a group of products. Some people move sideways into regulatory affairs, medical information, clinical quality assurance or safety writing, where the habit of tying every statement to a source document carries over directly.

Dear Hiring Manager,

I am applying for the Pharmacovigilance Specialist position on your drug safety team. For the past two years I have worked as a drug safety associate at a contract safety provider, handling intake, coding and narratives for three sponsors with products in immunology and respiratory medicine.

Most of my cases are postmarketing reports from medical information lines and patient support programs, plus serious adverse event reports from two ongoing phase 3 studies. I code in MedDRA and WHODrug every day and write narratives in Argus that my reviewing physicians can sign off without sending back for rework. My quality reviewer's error rate on my cases dropped steadily through my first year, and I now act as a second reviewer for newer associates on my team.

The part of the work I have pushed hardest on is follow-up. Early on I sent generic query letters and got generic silence back. I started writing short, specific questions tied to the gap in each case, such as the date a rash started relative to the first dose, and the answers came back faster and more complete. That change also made my seriousness and expectedness calls easier to defend.

I also volunteered for our team's E2B(R3) testing, which taught me how a field mapping error turns into a rejected submission and how to trace it back through the case record.

I would like to move to a sponsor where I can follow one product's safety profile over time and contribute to aggregate reports and signal reviews. Your pipeline in my two therapeutic areas is a strong fit for that goal. I would welcome the chance to talk about the role.

Sincerely, Jordan Ellis